{"id":42477,"date":"2025-09-29T17:45:26","date_gmt":"2025-09-29T09:45:26","guid":{"rendered":"https:\/\/flcube.com\/?p=42477"},"modified":"2025-09-29T17:45:27","modified_gmt":"2025-09-29T09:45:27","slug":"hua-medicine-secures-hong-kong-nda-acceptance-for-dorzagliatin-first%e2%80%91in%e2%80%91class-glucokinase-activator","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42477","title":{"rendered":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator"},"content":{"rendered":"\n<p><strong>China\u2011based Hua Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/2552:HKG\">HKG: 2552<\/a>)<\/strong> announced that the <strong>Hong\u202fKong Department of Health<\/strong> has accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>dorzagliatin<\/strong>, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-sets-dorzagliatin-apart\">What Sets Dorzagliatin Apart<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011of\u2011Its\u2011Kind GKA<\/strong> \u2013 Dorzagliatin repairs the body\u2019s glucose\u2011sensor, <strong>glucokinase (GK)<\/strong>, tackling the root cause of hyperglycaemia rather than merely masking symptoms.<\/li>\n\n\n\n<li><strong>Dual\u2011Indication Profile<\/strong> \u2013 Approved by China\u2019s NMPA in 2022 for:<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Monotherapy<\/strong> in drug\u2011na\u00efve T2D patients (first\u2011line therapy).<\/li>\n\n\n\n<li><strong>Combination therapy<\/strong> with metformin when metformin alone is insufficient.<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Long\u2011Term Glycaemic Control<\/strong> \u2013 By restoring GK function, the drug sustains glucose sensitivity, supporting durable disease management and potentially reducing complications.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-for-hua-medicine\">Strategic Significance for Hua Medicine<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regional Expansion<\/strong> \u2013 The Hong\u202fKong NDA acceptance marks a pivotal milestone in Hua Medicine\u2019s strategy to extend beyond the mainland Chinese market, potentially delivering its innovative therapy to a wider Asian patient base.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 With approvals in China (2022) and now Hong\u202fKong (2025), the company is building a solid regulatory foundation that could accelerate future approvals in other jurisdictions.<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong> \u2013 T2D remains the fastest\u2011growing chronic disease worldwide; dorzagliatin\u2019s first\u2011line and combination indications broaden its commercial footprint, positioning Hua Medicine for significant revenue growth.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-outlook\">Investor Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Credibility<\/strong> \u2013 The first\u2011in\u2011class GKA platform and successful regulatory milestones enhance investor confidence in Hua Medicine\u2019s innovation pipeline.<\/li>\n\n\n\n<li><strong>Market Potential<\/strong> \u2013 The drug\u2019s unique mechanism and broad indication set it apart from traditional anti\u2011diabetic therapies, potentially capturing a sizeable share of the high\u2011growth diabetes therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42480,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,1159,308,38,25],"class_list":["post-42477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hkg-2552","tag-hua-medicine","tag-market-approval-filings","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42477\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42477\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T09:45:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-29T09:45:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator\",\"datePublished\":\"2025-09-29T09:45:26+00:00\",\"dateModified\":\"2025-09-29T09:45:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477\"},\"wordCount\":280,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2906.webp\",\"keywords\":[\"Diabetes\",\"HKG: 2552\",\"Hua Medicine\",\"Market approval filings\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42477#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42477\",\"name\":\"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2906.webp\",\"datePublished\":\"2025-09-29T09:45:26+00:00\",\"dateModified\":\"2025-09-29T09:45:27+00:00\",\"description\":\"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42477\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42477#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42477","og_locale":"en_US","og_type":"article","og_title":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator","og_description":"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).","og_url":"https:\/\/flcube.com\/?p=42477","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-29T09:45:26+00:00","article_modified_time":"2025-09-29T09:45:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42477#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42477"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator","datePublished":"2025-09-29T09:45:26+00:00","dateModified":"2025-09-29T09:45:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42477"},"wordCount":280,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42477#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","keywords":["Diabetes","HKG: 2552","Hua Medicine","Market approval filings","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42477#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42477","url":"https:\/\/flcube.com\/?p=42477","name":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42477#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42477#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","datePublished":"2025-09-29T09:45:26+00:00","dateModified":"2025-09-29T09:45:27+00:00","description":"China\u2011based Hua Medicine (HKG: 2552) announced that the Hong\u202fKong Department of Health has accepted its New Drug Application (NDA) for dorzagliatin, the world\u2019s first approved glucokinase activator (GKA) for type\u202f2 diabetes (T2D).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42477#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42477"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42477#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","width":1080,"height":608,"caption":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42477#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hua Medicine Secures Hong Kong NDA Acceptance for Dorzagliatin, First\u2011In\u2011Class Glucokinase Activator"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42477"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42477\/revisions"}],"predecessor-version":[{"id":42481,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42477\/revisions\/42481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42480"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}